In the latest twist in the immunotherapy market, Merck (MRK) disclosed that its Keytruda cancer medicine helped previously untreated lung cancer patients live longer than chemotherapy in a late-stage trial, which may solidify its position as the leading drug maker in this lucrative market.

Although full data was not reported and the trial will continue to evaluate whether Keytruda can delay lung cancer from progressing, the disclosure is potentially quite significant for Merck. The company is increasingly relying on its cancer portfolio for growth and Keytruda is already a dominant lung cancer treatment. Last year, the drug, which is approved to treat other cancers, notched $3.8 billion in sales.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy